The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
Open accessAbstract
Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has been linked to disease development. A large number of kinase inhibitors are therefore currently under investigation in clinical trials, and so far seven inhibitors have been approved as anti-cancer drugs. In addition, kinase inhibitors are widely used as specific probes to study cell signaling, but systematic studies describing selectivity of these reagents across a panel of diverse kinases are largely lacking. Here we evaluated the specificity of 156 validated kinase inhibitors, including inhibitors used in clinical trials, against 60 human Ser/Thr kinases using a thermal stability shift assay. Our analysis revealed many unexpected cross-reactivities for inhibitors thought to be specific for certain targets. We also found that certain combinations of active-site residues in the ATP-binding site correlated with the detected ligand promiscuity and that some kinases are highly sensitive to inhibition using diverse chemotypes, suggesting them as preferred intervention points. Our results uncovered also inhibitor cross-reactivities that may lead to alternate clinical applications. For example, LY333′531, a PKCβ inhibitor currently in phase III clinical trials, efficiently inhibited PIM1 kinase in our screen, a suggested target for treatment of leukemia. We determined the binding mode of this inhibitor by x-ray crystallography and in addition showed that LY333′531 induced cell death and significantly suppressed growth of leukemic cells from acute myeloid leukemia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 983
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Kinetic and Catalytic Mechanisms of Protein Kinases
Adams, J. A. (2001) · Chemical Reviews · doi:10.1021/cr000230w · Cited by 627
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Vedadi, M., Niesen, F. H., Allali-Hassani, A., Fedorov, O. Y., Finerty, P. J., Wasney, G. A., Yeung, R., Arrowsmith, C., Ball, L. J., Berglund, H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605224103 · Cited by 589
Self-citationRusso, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
Targeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416
Duncia, J. V., Santella, J. B., Higley, C. A., Pitts, W. J., Wityak, J., Frietze, W. E., Rankin, F. W., Sun, J.-H., Earl, R. A., Tabaka, A. C., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00522-8 · Cited by 401
Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H., Neel, D. A., Rito, C. J., Singh, U., Stramm, L. E., Melikian-Badalian, A., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950588y · Cited by 339
Bertrand, J. A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H. M., & Flocco, M. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.031 · Cited by 319
Self-citationSchulze‐Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., & Kim, S. (1995) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340220408 · Cited by 279
Protein kinase C (PKC) family in cancer progression
Koivunen, J., Aaltonen, V., & Peltonen, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.03.033 · Cited by 261
Do aligned sequences share the same fold?
Abagyan, R. A., & Batalov, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1287 · Cited by 245
Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers
Capra, M., Nuciforo, P. G., Confalonieri, S., Quarto, M., Bianchi, M., Nebuloni, M., Boldorini, R., Pallotti, F., Viale, G., Gishizky, M. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3489 · Cited by 200
Pogacic, V., Bullock, A. N., Fedorov, O., Filippakopoulos, P., Gasser, C., Biondi, A., Meyer-Monard, S., Knapp, S., & Schwaller, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0320 · Cited by 189
Self-citationKinomics—structural biology and chemogenomics of kinase inhibitors and targets
Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A., & Hemmerle, H. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.028 · Cited by 175
Bullock, A. N., Debreczeni, J. E., Fedorov, O., Nelson, A. S., Marsden, B. D., & Knapp, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0504858 · Cited by 168
Self-citationKinomics: characterizing the therapeutically validated kinase space
Vieth, M., Sutherland, J. J., Robertson, D. H., & Campbell, R. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03477-x · Cited by 164
Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 152
Trans‐activation of the DNA‐damage signalling protein kinase Chk2 by T‐loop exchange
Oliver, A. W., Paul, A., Boxall, K. J., Barrie, S. E., Aherne, G. W., Garrett, M. D., Mittnacht, S., & Pearl, L. H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601209 · Cited by 136
Lierman, E., Folens, C., Stover, E. H., Mentens, N., Miegroet, H. V., Scheers, W., Boogaerts, M., Vandenberghe, P., Marynen, P., & Cools, J. (2006) · Blood · doi:10.1182/blood-2006-02-004457 · Cited by 132
Emanuel, S. L., Rugg, C. A., Gruninger, R. H., Lin, R., Fuentes‐Pesquera, A. R., Connolly, P. J., Wetter, S. K., Hollister, B. A., Kruger, W. W., Napier, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0882 · Cited by 127
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
Hans, C. P., Weisenburger, D. D., Greiner, T. C., Chan, W. C., Aoun, P. A., Cochran, G. T., Pan, Z., Smith, L. M., Lynch, J. C., Bociek, R. G., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800434 · Cited by 120
Adam, M., Pogačić, V., Bendit, M., Chappuis, R., Nawijn, M. C., Duyster, J., Fox, C. J., Thompson, C. B., Cools, J., & Schwaller, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2309 · Cited by 109
Self-citationStructure and Regulation of the Human Nek2 Centrosomal Kinase
Rellos, P., Ivins, F. J., Baxter, J. E., Pike, A. C. W., Nott, T. J., Parkinson, D.-M., Das, S. K., Howell, S. A., Fedorov, O., Shen, Q. Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609721200 · Cited by 108
Self-citationOverexpression of the oncogenic kinase Pim-1 leads to genomic instability.
Roh, M., Gary, B. D., Song, C., Said-Al-Naief, N. A. H., Tousson, A., Kraft, A. S., Eltoum, I., & Abdulkadir, S. A. (2003) · PubMed · Cited by 77
The protein kinase activity modulation sites:
Engh, R. A., & Bossemeyer, D. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00010-8 · Cited by 59
Thermal Denaturation: A Method to Rank Slow Binding, High-Affinity P38α MAP Kinase Inhibitors
Kroe‐Barrett, R., Regan, J. R., Proto, A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030120s · Cited by 47
Mayhood, T., & Windsor, W. T. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.07.032 · Cited by 46
Sheinerman, F. B., Giraud, E., & Laoui, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.074 · Cited by 45
Treatment of chronic myeloid leukemia with imatinib mesylate
Ohno, R. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0582-5 · Cited by 27
Kervinen, J., Ma, H., Bayoumy, S. S., Schubert, C., Milligan, C. M., Lewandowski, F. A., Moriarty, K., DesJarlais, R. L., Ramachandren, K., Wang, H., et al. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.03.018 · Cited by 18
Cited by
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationTargeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Metadata
- Authors
- Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Müller, S., Bullock, A. N., Schwaller, J., Sundström, M., & Knapp, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-12-18
- Volume
- 104
- Issue
- 51
- Pages
- 20523-20528
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2001097406
- Cited by
- 359
- References
- 41
- FWCI
- 28.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.